IPO: Decipher Biosciences Advances Prostate Genomic Testing

IPO: Decipher Biosciences Advances Prostate Genomic Testing

Decipher Biosciences, a commercial-stage precision urology oncology company, has filed with the U.S. Securities and Exchange Commission (SEC) to raise to raise up to $100 million in an IPO. Decipher’s prostate cancer genomic testing products surface information about the underlying biology of a patient’s tumor. The company applies machine learning algorithms to help physicians improve … Read more

Categories IPO

IPO: Cullinan Oncology, the Risk-managed Portfolio Of Cancer Drugs Startup

IPO: Cullinan Oncology, the Risk-managed Portfolio Of Cancer Drugs Startup

Cullinan Oncology, LLC, a Cambridge, MA-based company, plans to raise about $150 million by offering 8.3 million shares at a price range of $17 to $19. At the midpoint of this range, Cullinan’s market value would be $750 million, fully diluted. The company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology … Read more

Categories IPO

What Is Cell Squeeze Technology?

What Is Cell Squeeze Technology?

Cell Squeeze® is a commercial technology designed to manipulate individual cells (ie. a patient’s own cells) through mild perturbation that leaves the cells viable after mechanoporation – or the insertion of a cargo directly into a cell’s cytosol. SQZ Biotech is the sole developer of this technology. One early application consists of a microchip that … Read more

What Illumina Ventures’ Portfolio Says About The Science And Business Models Of The Future Care Delivery System

What Illumina Ventures’ Portfolio Says About The Science And Business Models Of The Future Care Delivery System

A look inside a leading venture capital firm’s portfolio is like a lens for understanding the current state of the future of healthcare. Illumina Ventures’ is an independently-managed, healthcare-focused venture firm in a strategic partnership with Illumina, Inc. The portfolio illustrates as much about business models as it does about the science behind synthetic biology. … Read more

Chinese Healthcare Companies Listed on Major U.S. Stock Exchanges

Chinese Healthcare Companies Listed on Major U.S. Stock Exchanges

Chinese companies have capitalized on the U.S.’s open capital markets for decades. As the U.S.-China relationship frays, examining Chinese integration in the healthcare and biotech sectors must involve U.S. national security. This table includes Chinese companies listed on the NASDAQ, New York Stock Exchange, and NYSE American, the three largest U.S. exchanges. As of October … Read more

In Conversation: Dr. Bradley Harding Discusses DNA-Computing

In Conversation: Dr. Bradley Harding Discusses DNA-Computing

Dr. Bradley Harding is a scientist specializing in DNA-based computing. His research, recently published in the prestigious journal Nano Letters, holds the potential to advance the field reusable biodevices controlled by logical operations. Dr. Harding’s research was co-supervised by the University of the Sunshine Coast’s Dr Joanne Macdonald and Dr Nina Pollak, assisted by collaborator … Read more

IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare

IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare

U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures … Read more

Categories IPO